The ANTICOV clinical trial aimed to identify treatments that could be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low-resource settings.


The trial was launched in September 2020 in 13 countries by the ANTICOV consortium. The consortium included 27 prominent global research and development organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi).


One of the largest multi-country trials focusing exclusively on mild and moderate cases of COVID-19, ANTICOV helped address the relative neglect of clinical research during the COVID-19 pandemic in Africa, Asia, and Latin America.  ANTICOV employed an innovative ‘adaptive platform’ trial design which allowed the consortium to add or remove treatments as evidence emerged.

Clinical trial tracker

AVAREF and ANTICOV: Accelerating regulatory approval for COVID-19 treatments in Africa

How do you obtain the approval to quickly launch a clinical trial in 13 African countries while ensuring that the most stringent ethical standards are respected? Watch this video to find out.

see our latest news




Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland.

  • European and Developing Countries Clinical Trials Partnership (EDCTP2), Europe 
  • Federal Ministry of Education and Research (BMBF) through KfW, Germany 
  • Starr International Foundation, Switzerland 
  • Stavros Niarchos Foundation (SNF) 
  • UK aid, UK 
  • Unitaid, Switzerland 
  • Other private foundations and individuals